Library / Search & Research Inquiry
Search the Scientific Record
Query graded findings, peer-reviewed papers, clinical trials, and decision ledgers across the archive — or spawn a new autonomous research branch for any unexplored question.
Public scientific archive — do not enter names, dates of birth, or personal medical identifiers. Organises published research; not medical advice. Privacy & copyright notice.
Grounded synthesis for “Rapamycin & mTOR ovarian reserve”
In Ovarian Reserve and Primordial Follicle Activation [1], In Vitro Activation (IVA) with Mechanical Fragmentation carries a "Trial only" verdict (Prospective case series of 27-37 POI patients): Promoted follicle growth and successfully yielded oocyte retrieval, successful pregnancies, and live births — Shows clinical potential for select POI/DOR patients, but evidence is restricted to small, non-randomized case series. In Ovarian Reserve and Primordial Follicle Activation [1], mTOR Pathway Inhibition (Everolimus) carries a "Lab only" verdict (Xenotransplantation model studies (2026)): Successfully preserved dormant follicle pool and enhanced graft longevity — Valuable for tissue longevity and chemotherapy protection, though human clinical trial data for preservation remains pending.
[T1 (debated)] In a meta-analysis of seven randomized controlled trials involving 422 women with poor ovarian reserve or ovarian insufficiency, intraovarian autologous platelet-rich plasma (PRP) significantly improved surrogate reserve biomarkers (antral follicle count MD 0.81, AMH SMD 0.91, FSH MD -5.72 mIU/mL) but failed to significantly improve pregnancy rates compared to controls. [2] [3] [T1] Mammalian target of rapamycin (mTOR) signaling regulates primordial follicle activation, and unchecked hyperactivation of this pathway accelerates exhaustion of the dormant ovarian reserve. [4] [5] [T1] Coenzyme Q10 pretreatment significantly improves clinical pregnancy rates and oocyte yield while reducing cycle cancellation and miscarriage rates in women with diminished ovarian reserve undergoing IVF/ICSI, based on a meta-analysis of 1529 participants. [6] [7]
Calibrated baseline benchmark in Primordial Follicle Activation and Ovarian Tissue Engineering [8]: 20.0%–30.0% — Proportion of women with premature ovarian insufficiency possessing residual microscopic primordial follicles upon ovarian biopsy (Huber et al., 2021).
Matched interventions in the Evaluated Decision Ledger
| Intervention / Lever | Verdict | Best evidence & measured effect | Discipline |
|---|---|---|---|
| In Vitro Activation (IVA) with Mechanical FragmentationMechanical disruption of the ovarian cortex to disrupt Hippo signaling, converting G-actin to F-actin and awakening dormant primordial follicles. | Trial only | Promoted follicle growth and successfully yielded oocyte retrieval, successful pregnancies, and live birthsProspective case series of 27-37 POI patients | Ovarian Reserve and Primordial Follicle Activation |
| mTOR Pathway Inhibition (Everolimus)Pharmacological suppression of mTOR signaling in xenotransplanted human ovarian tissue to prevent premature follicle activation and preserve the dormant pool. | Lab only | Successfully preserved dormant follicle pool and enhanced graft longevityXenotransplantation model studies (2026) | Ovarian Reserve and Primordial Follicle Activation |
| Mesenchymal Stem Cell-Derived Extracellular Vesicles (MSC-Exos)Targeting apoptosis, autophagy, and oxidative stress pathways to ameliorate premature ovarian failure. | Lab only | Elevated estrogen levels, reduced FSH, and restored estrous cyclicityPreclinical animal models (2023/2026) | Ovarian Reserve and Primordial Follicle Activation |
| DuoStim (Follicular + Luteal Double Stimulation)Starting a second gonadotropin stimulation 2–5 days after the first retrieval within the same menstrual cycle, using endogenous luteal progesterone to prevent premature LH surges. | Supported | Doubles mature oocytes and euploid blastocysts harvested in a single calendar monthVaiarelli et al., Hum Reprod 2020 (n=827 poor-prognosis patients) | Ovarian Reserve & Oocyte Cryopreservation |
Graded findings (24)
Pharmacological mTORC1 inhibition via rapamycin suppresses premature primordial follicle activation in animal models, supporting clinical trials examining low-dose rapamycin to slow ovarian reserve depletion in women.
Suppression of mTORC1 preserves ovarian quiescence in preclinical models, but human clinical translation for longevity of the ovarian reserve remains experimental.
- Effect of Rapamycin in Ovarian Aging (Columbia University, 2023, rct)
- Rapamycin‐sensitive mTORC1 signaling is involved in physiological primordial follicle activation in mouse ovary (Molecular Reproduction and Development, 2013, animal)
- T1 · Synthesis of trialsSenolytic and Anti-Aging Ovarian Therapeutics →
Mammalian target of rapamycin (mTOR) signaling regulates primordial follicle activation, and unchecked hyperactivation of this pathway accelerates exhaustion of the dormant ovarian reserve.
Establishes mTOR signaling as a key regulatory pathway governing dormant follicle recruitment and premature ovarian exhaustion.
- Enhanced glycolysis in granulosa cells promotes the activation of primordial follicles through mTOR signaling (Cell Death and Disease, 2022, animal)
- Advances in human primordial follicle activation and premature ovarian insufficiency. (Reproduction (Cambridge, England), 2020, systematic review)
- Molecular Mechanisms Underlying the Activation of Mammalian Primordial Follicles (Endocrine Reviews, 2009, unknown)
- T5 · Preclinical or mechanisticDebatedPrimordial Follicle Activation and Ovarian Tissue Engineering →
Ovarian tissue cryopreservation and in vitro organotypic culture trigger aberrant primordial follicle activation via the PI3K/PTEN/Akt and mTOR pathways, which can be mitigated by pharmacological inhibitors such as rapamycin and LY294002.
Modulation of Akt and mTOR signalling is critical to prevent follicle burnout and reserve exhaustion during ovarian tissue preservation and culture procedures.
- Pharmacological inhibition of the PI3K/PTEN/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro culture. (Journal of ovarian research, 2021, animal)
Rapamycin administration (5 mg/kg) in female mice suppresses phosphorylation of the mTOR signaling cascade and preserves the primordial follicle pool by inhibiting excessive follicle activation.
Demonstrates the pharmacological preservation of ovarian reserve via targeted mTOR pathway inhibition in vivo.
- Effects of Rapamycin on the activation and growth of primordial follicles in mice (Chin J Reprod Contracep, 2020, animal)
The aim of this paper was to study the role of phosphoinositide 3-kinase(PI3 K), protein kinase B(Akt) and mamma-lian target of rapamycin(mTOR) in the inhibition of premature ovarian failure induced by D-galactose(D-gal) in mice model by ginsenoside Rg_1(Rg_1).
Extracted from primary animal literature (2020, 10 citations).
- [Effect of ginsenoside Rg_1 in delaying premature ovarian failure induced by D-gal in mice through PI3K/Akt/mTOR autophagy pathway]. (Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2020, animal)
Senotherapeutic interventions, encompassing senolytics (such as dasatinib with quercetin, navitoclax, and fisetin) and senomorphics (including rapamycin, metformin, and melatonin), show preclinical efficacy in dampening SASP-driven ovarian fibrosis and preserving ovarian reserve, but human clinical translation remains unverified.
Synthesizes preclinical geroscience findings targeting ovarian senescent cells while emphasizing the lack of completed clinical validation in human fertility.
- Ovarian aging: Mechanisms and strategies to extend reproductive lifespan (Chinese Medical Journal BioMed, 2026, expert opinion)
- Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives. (Current opinion in pharmacology, 2026, expert opinion)
- T1 · Synthesis of trialsMicronutrient, Antioxidant & Mitochondrial Fertility Supplementation →
Coenzyme Q10 pretreatment significantly improves clinical pregnancy rates and oocyte yield while reducing cycle cancellation and miscarriage rates in women with diminished ovarian reserve undergoing IVF/ICSI, based on a meta-analysis of 1529 participants.
CoQ10 is widely studied as a mitochondrial supplement to restore egg quality in advanced age or diminished ovarian reserve.
- Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis (Annals of Medicine, 2024, systematic review)
In vitro activation (IVA) combined with autologous transplantation is emerging as a novel experimental approach for primary ovarian insufficiency and diminished ovarian reserve, though clinical evidence remains limited to small case series.
Highlights the translational application and clinical limitations of surgical and mechanical IVA techniques for fertility restoration.
- Regenerative approaches in ovarian rejuvenation: hope for fertility restoration (International Journal of Reproduction Contraception Obstetrics and Gynecology, 2026, systematic review)
- Fertility preservation in patients with Turner syndrome: a SWOT analysis (Reproductive BioMedicine Online, 2025, systematic review)
- In Vitro Follicular Activation and Stem Cell Therapy as a Novel Treatment Strategies in Diminished Ovarian Reserve and Primary Ovarian Insufficiency. (Frontiers in endocrinology, 2020, expert opinion)
- In vitro activation of ovarian cortex and autologous transplantation: A novel approach to primary ovarian insufficiency and diminished ovarian reserve (Human Reproduction Open, 2020, systematic review)
- T3 · Observational, largeDebatedMicronutrient, Antioxidant & Mitochondrial Fertility Supplementation →
In a prospective cohort study of 103 women with diminished ovarian reserve, 8 weeks of DHEA supplementation (25 mg three times a day) increased serum testosterone, DHEAS, and androgen receptor mRNA expression in granulosa cells.
Explains the potential molecular mechanism underlying DHEA responsiveness in poor ovarian reserve.
- The effect of dehydroepiandrosterone supplementation on ovarian response is associated with androgen receptor in diminished ovarian reserve women (Journal of Ovarian Research, 2017, cohort)
In uncontrolled prospective cohorts of women with poor ovarian reserve, intraovarian autologous platelet-rich plasma injection was associated with increases in antral follicle count, anti-Mullerian hormone levels, and retrieved oocyte counts.
Observational cohort studies suggest improved markers of ovarian reserve and oocyte yield, but these studies lack a randomized control group.
- Intraovarian platelet-rich plasma injection in poor responders (JBRA, 2024, cohort)
- Intraovarian platelet-rich plasma injection in poor responders (The Journal of Reproduction, 2023, cohort)
- Efficacy of autologous platelet rich plasma for ovarian rejuvenation in infertile women having poor ovarian reserve (International Journal of Reproduction Contraception Obstetrics and Gynecology, 2022, cohort)
- T3 · Observational, largeOvarian Reserve & Oocyte Cryopreservation →
BackgroundAnti-cancer therapy is often a cause of premature ovarian insufficiency and infertility since the ovarian follicle reserve is extremely sensitive to the effects of chemotherapy and radiotherapy.
Extracted from primary literature (2019).
- Ovarian damage from chemotherapy and current approaches to its protection. (Human reproduction update, 2019, expert opinion)
- T3 · Observational, largeOvarian Reserve & Oocyte Cryopreservation →
Advanced maternal age (AMA; >35 year) is associated with a decline in both ovarian reserve and oocyte competence.
Extracted from primary literature (2019).
- Advanced Maternal Age in IVF: Still a Challenge? The Present and the Future of Its Treatment. (Frontiers in endocrinology, 2019, in vitro)
Vitamin D supplementation (50,000 units weekly for 3 months) in women with diminished ovarian reserve and baseline deficiency may increase serum Anti-Müllerian Hormone (AMH) levels.
While one study shows a significant increase in AMH levels, the authors suggest this may occur without necessarily changing the antral follicle count or true ovarian reserve.
- Does vitamin D supplementation improve ovarian reserve in women with diminished ovarian reserve and vitamin D deficiency: a before-and-after intervention study (BMC Endocrine Disorders, 2021, cohort)
- T4 · Observational, small or case-basedInter-Transfer Interval: Immediate vs. Delayed Frozen Embryo Transfer (FET) & Endometrial Reset →
Natural cycle IVF, utilizing modified protocols (e.g., Clomiphene citrate), provides an alternative for women with low ovarian reserve by leveraging the body's natural follicular selection.
This approach offers a lower-intensity alternative to conventional hyperstimulation for patients with diminished ovarian reserve.
- Natural Cycle IVF can be a successful treatment alternative for patients with low ovarian reserve (JBRA, 2013, case series)
- T4 · Observational, small or case-basedInter-Transfer Interval: Immediate vs. Delayed Frozen Embryo Transfer (FET) & Endometrial Reset →
Anti-Müllerian hormone (AMH) serves as a more robust predictor of ovarian reserve than FSH in women aged 35 years and older.
Marker reliability for ovarian reserve assessment changes with advanced maternal age, affecting how clinicians counsel women regarding IVF success rates.
- SERUM AMH, INHIBIN B, FSH AND ESTRADIOL PROFILE IN WOMEN SEEKING CONCEPTION THROUGH IN VITRO FERTILIZATION IN NIGERIA (Journal of Health Medicine and Nursing, 2019, cross sectional)
- T5 · Preclinical or mechanisticOvarian Reserve and Primordial Follicle Activation →
Pharmacological inhibition of the mTOR pathway with everolimus suppresses primordial follicle activation in xenotransplanted human ovarian cortical tissue, successfully preserving the dormant follicle pool and enhancing graft longevity.
Shows that preventing premature activation through targeted pathway inhibition protects the ovarian reserve following transplantation.
- T5 · Preclinical or mechanisticPrimordial Follicle Activation and Ovarian Tissue Engineering →
Enhanced glycolytic flux in granulosa cells activates primordial follicles through mTOR signaling and downstream Akt/FOXO3a phosphorylation in mouse and human ovarian tissue models.
Demonstrates an energetic metabolic mechanism linking granulosa cell glycolysis to mTOR-mediated activation of dormant follicles.
- Enhanced glycolysis in granulosa cells promotes the activation of primordial follicles through mTOR signaling (Cell Death and Disease, 2022, animal)
- T5 · Preclinical or mechanisticOvarian Reserve and Primordial Follicle Activation →
Gestational exposure to dibutyl phthalate (DBP) impairs the ovarian reserve by driving METTL14-dependent m6A hypermethylation, which prematurely activates the PI3K-AKT-FOXO3a signaling axis and causes primordial follicle depletion.
Highlights how environmental endocrine disruptors can induce premature follicular activation and a POI-like phenotype.
- Gestational dibutyl phthalate exposure impairs the ovarian reserve in offspring mice through METTL14-m6A-mediated PI3K-AKT-FOXO3a activation. (Journal of hazardous materials, 2026, animal)
- T5 · Preclinical or mechanisticPrimordial Follicle Activation and Ovarian Tissue Engineering →
In mouse ovarian tissue in vitro, HDAC6 acts as a negative regulator of mTOR, and its inhibition promotes primordial follicle activation by simultaneously upregulating mTOR expression and oocyte PI3K activity.
Epigenetic modulation of the PI3K/mTOR axis provides a potential targeted mechanism for controlled in vitro activation of dormant primordial follicles.
- HDAC6 regulates primordial follicle activation through mTOR signaling pathway (Cell Death and Disease, 2021, unknown)
- T5 · Preclinical or mechanisticDebatedPrimordial Follicle Activation and Ovarian Tissue Engineering →
Inhibition of p53 promotes primordial follicle activation and reduces the dormant follicle reserve in neonatal mouse ovaries by upregulating downstream effectors of the mTOR pathway, an effect prevented by co-inhibition of mTOR.
Clarifies the regulatory relationship between tumor suppressors and the mTOR pathway in primordial follicle dormancy and activation.
- [p53 regulates primordial follicle activation through the mTOR signaling pathway]. (Sheng li xue bao : [Acta physiologica Sinica], 2023, animal)
- [p53 regulates primordial follicle activation through the mTOR signaling pathway]. (PubMed, 2023, in vitro)
- T5 · Preclinical or mechanisticSenolytic and Anti-Aging Ovarian Therapeutics →
Downregulation of the Irs1/Pi3k/Akt1/Mtor pathway and maintained Foxo3a expression in Ames dwarf mice is associated with delayed ovarian aging.
Highlights the physiological link between suppressed growth signaling pathways (including mTOR) and extended ovarian lifespan.
- Primordial follicle activation in the ovary of Ames dwarf mice (Journal of Ovarian Research, 2014, animal)
In human ovarian cortical biopsies from 17 women, rapamycin mitigates chemotherapy-induced hyperactivation of PI3K signalling in primordial follicles in vitro.
mTOR inhibition represents a targeted approach to prevent follicle exhaustion, though functional oocyte quality outcomes require further investigation.
- Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro. (Human reproduction (Oxford, England), 2024, in vitro)
- T5 · Preclinical or mechanisticPrimordial Follicle Activation and Ovarian Tissue Engineering →
Dysfunction of leptin receptor signaling in female mice induces premature ovarian follicle depletion accompanied by excessive ovarian PTEN/PI3K/Akt/mTOR pathway activation.
Demonstrates that chronic systemic hyperactivation of the PTEN/Akt/mTOR pathway results in pathologically accelerated follicle exhaustion.
- Follicle loss and PTEN/PI3K/mTOR signaling pathway activated in LepR-mutated mice. (Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2019, animal)
In a meta-analysis of seven randomized controlled trials involving 422 women with poor ovarian reserve or ovarian insufficiency, intraovarian autologous platelet-rich plasma (PRP) significantly improved surrogate reserve biomarkers (antral follicle count MD 0.81, AMH SMD 0.91, FSH MD -5.72 mIU/mL) but failed to significantly improve pregnancy rates compared to controls.
High-level randomized evidence indicates that biomarker changes after intraovarian PRP do not reliably translate into clinical pregnancy success.
- Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials (Frontiers in Endocrinology, 2026, systematic review)
Papers, preprints & clinical trials (24)
- mTOR Inhibition via Low-Dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve? — Sills ES, Harrity C, Wood SH · Journal of personalized medicine · 2023 · expert opinion · 4 citations
DOI: 10.3390/jpm13071147 · Read abstract & full text at official source ↗
Indexed in: mTOR Pathway Modulation & Follicular Longevity - mTOR Inhibition via Low-dose, Pulsed Rapamycin with Intraovarian Condensed Platelet Cytokines: An Individualized Protocol to Recover Diminished Reserve — Sills ES, Harrity C, Wood SH · Preprints.org · 2023 · expert opinion
DOI: 10.20944/preprints202306.1357.v1 · Read abstract & full text at official source ↗
Indexed in: mTOR Pathway Modulation & Follicular Longevity - Rapamycin maintains the primordial follicle pool and protects ovarian reserve against cyclophosphamide-induced damage — Xiuying Chen, Zhijing Tang, Haiyun Guan · Journal of Reproduction and Development · 2022 · animal · 23 citations
DOI: 10.1262/jrd.2022-001 · Read abstract & full text at official source ↗
- L26/O-214 Everolimus preserves xenotransplanted human ovarian tissue by inhibiting primordial follicle activation via the mTOR/S6/eIF4B signaling pathway — Y. Kuang, Y. Guan, R. Shen · Human Reproduction · 2026 · animal
DOI: 10.1093/humrep/deag083.212 · Read abstract & full text at official source ↗
- The mTOR Inhibitor Rapamycin Counteracts Follicle Activation Induced by Ovarian Cryopreservation in Murine Transplantation Models — Jules Bindels, Marlyne Squatrito, Laëtitia Bernet · Medicina · 2023 · animal · 12 citations
DOI: 10.3390/medicina59081474 · Read abstract & full text at official source ↗
- Rapamycin prevents cyclophosphamide-induced ovarian follicular loss and potentially inhibits tumour proliferation in a breast cancer xenograft mouse model. — Tanaka Y, Amano T, Nakamura A · Human reproduction (Oxford, England) · 2024 · rct · 13 citations
DOI: 10.1093/humrep/deae085 · Read abstract & full text at official source ↗
- Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve — Oren Kashi, Hadassa Roness, Itai Spector · Human Reproduction · 2023 · rct · 47 citations
DOI: 10.1093/humrep/dead064 · Read abstract & full text at official source ↗
- Pharmacological inhibition of the PI3K/PTEN/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro culture. — Terren C, Nisolle M, Munaut C · Journal of ovarian research · 2021 · animal · 30 citations
DOI: 10.1186/s13048-021-00846-5 · Read abstract & full text at official source ↗
- Rapamycin treatment maintains developmental potential of oocytes in mice and follicle reserve in human cortical fragments grafted into immune-deficient mice. — Yorino Sato, Kawamura K · Molecular and cellular endocrinology · 2020 · animal · 26 citations
DOI: 10.1016/j.mce.2019.110694 · Read abstract & full text at official source ↗
- Rapamycin‐sensitive mTORC1 signaling is involved in physiological primordial follicle activation in mouse ovary — Yuanyuan Tong, Fei Yue Li, Yi Lu · Molecular Reproduction and Development · 2013 · animal · 56 citations
DOI: 10.1002/mrd.22267 · Read abstract & full text at official source ↗
- Progress in research on the effects of Platelet-Rich Plasma (PRP) ovarian injection on early ovarian reserve dysfunction and premature ovarian insufficiency — Min Hu, Liangdan Tang, Ying Chen · Journal of Ovarian Research · 2026 · systematic review · 2 citations
DOI: 10.1186/s13048-026-01977-3 · Read abstract & full text at official source ↗
- Fisetin Attenuates D-Gal-Induced Ovarian Aging by Modulating Mitophagy via the AMPK/mTOR Pathway. — Dong J, Zhu Y, Li Z · Antioxidants (Basel, Switzerland) · 2026 · animal
DOI: 10.3390/antiox15050602 · Read abstract & full text at official source ↗
Indexed in: mTOR Pathway Modulation & Follicular Longevity - Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro. — Rosario R, Stewart HL, Spears N · Human reproduction (Oxford, England) · 2024 · in vitro · 32 citations
DOI: 10.1093/humrep/dead255 · Read abstract & full text at official source ↗
Indexed in: Senolytic and Anti-Aging Ovarian Therapeutics - Impact of first chemotherapy exposure on follicle activation and survival in human cryopreserved ovarian tissue — Melody Devos, P Dia. Vidal, Jason Bouziotis · Human Reproduction · 2023 · 20 citations
DOI: 10.1093/humrep/dead013 · Read abstract & full text at official source ↗
- [Effect of ginsenoside Rg_1 in delaying premature ovarian failure induced by D-gal in mice through PI3K/Akt/mTOR autophagy pathway]. — Liu XH, Zhao ZH, Zhou Y · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica · 2020 · animal · 10 citations
DOI: 10.19540/j.cnki.cjcmm.20200901.405 · Read abstract & full text at official source ↗
Indexed in: mTOR Pathway Modulation & Follicular Longevity - ROS: their roles in diminished ovarian reserve — Xin Chen, 刘丹卓 · Frontiers in Endocrinology · 2026 · expert opinion · 2 citations
DOI: 10.3389/fendo.2026.1823452 · Read abstract & full text at official source ↗
Indexed in: Dehydroepiandrosterone - Gestational dibutyl phthalate exposure impairs the ovarian reserve in offspring mice through METTL14-m6A-mediated PI3K-AKT-FOXO3a activation. — Zhang Y, Yi F, He Y · Journal of hazardous materials · 2026 · animal · 1 citations
DOI: 10.1016/j.jhazmat.2026.142061 · Read abstract & full text at official source ↗
- Influence of vitamin D supplementation on ovarian reserve as reflected by anti-Müllerian hormone levels: a meta-analysis of randomized controlled trials — Sitian Fang, Yijia Li, Xinyu Fan · Frontiers in Endocrinology · 2026 · systematic review · 1 citations
DOI: 10.3389/fendo.2026.1832704 · Read abstract & full text at official source ↗
Indexed in: Micronutrient Supplementation in Ovarian Aging - Intraovarian injection of autologous platelet-rich plasma combined with peripheral blood mononuclear cells improves ovarian function in advanced-age women with diminished ovarian reserve: a clinical retrospective cohort and single-cell transcriptomic analysis. — Wu H, Zhang Z, Ruan L · Journal of ovarian research · 2026 · cohort
DOI: 10.1186/s13048-026-02006-z · Read abstract & full text at official source ↗
Indexed in: Autologous Ovarian Rejuvenation Therapies - L26/P-409 Maximizing oocyte pool in diminished ovarian reserve: A longitudinal analysis of cumulative yields under a national public funding program for elective cryopreservation — Or Touval, R. Rahav-Koren, D. Homossany · Human Reproduction · 2026 · cohort
DOI: 10.1093/humrep/deag083.743 · Read abstract & full text at official source ↗
Indexed in: Ovarian Reserve & Oocyte Cryopreservation - Fertility preservation in women: enhanced neovascularization, follicle viability and tissue integrity in cryopreserved human ovarian cortex by remaining medulla tissue — Laura Rafensteiner, Sabine Eberhart, Alexandra Waldhauer · Journal of Ovarian Research · 2026 · in vitro
DOI: 10.1186/s13048-026-02063-4 · Read abstract & full text at official source ↗
- Oocyte Cryopreservation in Young Women with Low Ovarian Reserve Following Repeated Bilateral Ovarian Cystectomy — Cepi Teguh Pramayadi, Rahmi Isman · Indonesian Journal of Obstetrics and Gynecology · 2026 · expert opinion
DOI: 10.32771/inajog.v14i2.3109 · Read abstract & full text at official source ↗
Indexed in: Ovarian Reserve & Oocyte Cryopreservation - Efficacy of intraovarian autologous platelet-rich plasma in women with poor ovarian reserve or ovarian insufficiency: a meta-analysis of randomized controlled trials — Yuan Fang, Chunhua Liu, Zixin He · Frontiers in Endocrinology · 2026 · systematic review
DOI: 10.3389/fendo.2026.1827041 · Read abstract & full text at official source ↗
Indexed in: Autologous Ovarian Rejuvenation Therapies - Micro-CT and machine learning: a high-throughput alternative to histology for follicle reserve assessment in cryopreserved ovarian tissue — Katri Knuus, Mai Nguyen, Markus Hannula · Figshare · 2026 · unknown
DOI: 10.6084/m9.figshare.c.8250574 · Read abstract & full text at official source ↗
Indexed in: Oocyte Morphology Assessment
Disciplines & indexed entities
Review of pharmacological and surgical interventions, such as In Vitro Activation (IVA), designed to recruit dormant follicles in cases of diminished ovarian reserve.
Follicular dynamics, ovarian aging across the reproductive lifespan, oocyte vitrification, warming survival, and cumulative live birth outcomes.
- Ovarian Reserve0 findings
Biomarkers, diagnostic imaging, and quantitative methods for assessing remaining primordial follicle pools across reproductive aging.
- Ovarian Reserve0 findings
Physiological assessment of diminished ovarian reserve and the biochemical mechanisms of androgen supplementation on folliculogenesis.
Evaluates pharmacological interventions targeting senescent ovarian stromal cells, nicotinamide adenine dinucleotide (NAD+) precursors, mTOR inhibitors, and antioxidants for mitigating age-related oocyte aneuploidy.
Focuses on in vitro follicle activation (IVA), signaling pathway modulation (Akt/PTEN/mTOR pathway), and tissue-engineered bioartificial ovaries for germline preservation and activation.
Mechanistic and translational studies of mTORC1 inhibition (rapamycin/sirolimus) on primordial follicle activation and reproductive aging.
Assesses the pharmacological inhibition of mTORC1 via rapamycin and rapalogs to balance primordial follicle quiescence against activation, mitigating accelerated follicular exhaustion.
- Autologous Ovarian Rejuvenation Therapies19 findings
Investigates intraovarian injections of autologous platelet-rich plasma (PRP), bone marrow-derived stem cells, and cell-free secretomes or exosomes to restore folliculogenesis in diminished ovarian reserve.
Mechanistic analysis of residual follicular luteinisation, androgen-to-oestrogen ratios, and gonadotropin receptor down-regulation in consecutive stimulation.
Follicular wave recruitment kinetics underlying DuoStim protocols and random-start cycles within single or adjacent menstrual cycles.
Evidence regarding the impact of coenzyme Q10, vitamin D, folic acid, and antioxidant supplementation on mitochondrial function in aging oocytes.
Comparative evaluation of rest periods versus immediate consecutive cycles on mature oocyte retrieval and ovarian response metrics in diminished ovarian reserve cohorts.
Paracrine signaling, dormant primordial follicle activation, and clinical trial evaluation of intraovarian autologous biologics in diminished ovarian reserve.
Evaluates autologous platelet concentrates, alpha-granule growth factors, and injection protocols targeted at stimulating residual primordial follicles in diminished ovarian reserve and premature ovarian insufficiency.
Synthesise the peer-reviewed record on rejuvenating both sperm as well as ovarian: systematic reviews, randomised clinical trials, large cohort studies, quantitative effect sizes, safety signals, and active trials.
- Reproductive Medicine & Human Fertility12 findings
Physiology, epidemiology, pathology, and clinical interventions in human reproduction across the lifespan, including gametogenesis, ovarian reserve, cryopreservation, endometrial receptivity, andrology, assisted reproductive technology, maternal-fetal medicine, and translational reproductive biology.
In vitro gametogenesis, mitochondrial replacement therapy, ovarian tissue cryopreservation and transplantation, mTOR modulation, and intraovarian biologics.
Cortical strip freezing, vitrification versus slow freezing, revascularisation kinetics, endocrine restoration, and fertility preservation.
Molecular markers of follicular depletion, mitochondrial dysfunction in oocytes, and the relationship between biological maternal age clocks and obstetric complications.
Surgical harvesting, slow-cooling and vitrification protocols of ovarian cortical strips, followed by orthotopic or heterotopic transplantation and evaluation of endocrine restoration and fertility outcomes.
Engineered 3D hydrogels, decellularized extracellular matrices, and microfluidic systems supporting follicle encapsulation, survival, and maturation.
Reconstitution of the complete female gametogenesis pathway in vitro using somatic support cells, synthetic niches, and organoid cultures.
- Melatonin and Ovarian Chronobiology0 findings
Study of melatonin's role as a direct free radical scavenger and its activation of antioxidant enzymes within the pre-ovulatory follicle.
- VIBRANT Rapamycin Ovarian Aging Study (NCT05836025) · United States (trial)
Columbia University randomized placebo-controlled trial testing 5 mg weekly oral rapamycin (mTOR inhibitor) to slow follicular burnout.
- Federal Reserve System · United States (company)
Central banking system of the United States conducting monetary policy, regulating commercial banks, and maintaining systemic payment stability.
Branch: Macroeconomics, Political Economy & Economic History
- Centre de Physique Théorique (CPT Luminy, Aix-Marseille) · France (lab)
Leading European center for loop quantum gravity and spin foams, where Carlo Rovelli and collaborators developed covariant quantum gravity.
Branch: Loop Quantum Gravity, Spin Foams, Causal Dynamical Triangulations & Asymptotic Safety
- Gameto Inc. (Fertilo Engineered IVM) · United States (company)
Biotechnology company using human iPSC-derived ovarian support cells (Fertilo) to mature immature autologous eggs outside the body (Phase 3 NCT06858111).
- Stacy S. McGaugh · United States (person)
Professor and Chair of Astronomy at Case Western Reserve University, leading researcher on galaxy kinematics, the Radial Acceleration Relation, and SPARC.
Branch: Modified Newtonian Dynamics (MOND), Relativistic Extensions & Galactic Dynamics